Overview

Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.

Status:
Completed

Trial end date:
1997-03-01

Target enrollment:

Participant gender:

Summary

The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral infarction in patients who had suffered a cerebral infarction 1 to 6 months prior to entering the trial.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Cilostazol